This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: The infection risks of recent biologics for psoriasis remain insufficiently studied. OBJECTIVE: To simultaneously assess inpatient- and outpatient-managed infection risks of biologics in psoriasis. METHODS: Using the French National Health Data System (2013-2022), we conducted a cohort study of 39,669 adults with psoriasis who were new users of biologics. Biologics were compared regarding (i) time to hospitalization for infection, (ii) time to first outpatient anti-infective dispensation, and (iii) proportion of days covered by anti-infectives over 2 years. RESULTS: During biologic exposure, inpatient-managed infections occurred at 27.1 per 1000 person-years, and median systemic anti-infective coverage was low (5.5%; 95% CI: 2.6-11.5). Using the most frequently prescribed biologic, adalimumab, as reference: (i) inpatient-managed infection risk was lower with ustekinumab, secukinumab, and risankizumab; (ii) first antibacterial use was higher with certolizumab and lower with ustekinumab, guselkumab, and risankizumab; and (iii) antibacterial coverage was lower with ustekinumab, secukinumab, ixekizumab, risankizumab, and tildrakizumab; higher antimycotic coverage was observed with interleukin-17i biologics. LIMITATIONS: Claims data lacks clinical information and limits our assessment to systemic anti-infectives. CONCLUSION: Biologics are associated with low overall infection risks. Among biologics, ustekinumab and interleukin-23 inhibitors show the lowest overall risk (time to the first inpatient/outpatient event).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: